Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

SUMMARY The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate with both carcinogenesis and response to targeted drugs. Several molecular alterations have been defined as “driver mutations”. These are responsible for both the initiation and maintenance of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2010-11, Vol.36, p.S21-S29
Hauptverfasser:	Bronte, Giuseppe, Rizzo, Sergio, La Paglia, Laura, Adamo, Vincenzo, Siragusa, Sergio, Ficorella, Corrado, Santini, Daniele, Bazan, Viviana, Colucci, Giuseppe, Gebbia, Nicola, Russo, Antonio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Algorithms Antineoplastic Combined Chemotherapy Protocols - therapeutic use Driver mutations EGFR Gene Expression Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Molecular Targeted Therapy - methods Mutation Oncogene Proteins, Fusion - genetics Phosphatidylinositol 3-Kinases Predictive Value of Tests Prognosis Protein-Tyrosine Kinases - antagonists & inhibitors Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Receptor, Epidermal Growth Factor - genetics Treatment Outcome Tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!